Keranova

Keranova is a private, pre-revenue French medtech innovator creating a disruptive robotic surgical suite for ophthalmology. Its flagship FemtoMatrix® platform, based on 14 patented innovations, aims to automate cataract surgery via a novel process called Photoemulsification®, potentially supplanting current manual techniques. Backed by notable life science investors and a global scientific advisory board, the company is positioning itself to set a new standard in surgical performance, though it faces significant commercial and regulatory hurdles typical of novel medical devices.

FemtoMatrix® platform integrating ultra-fast (femtosecond) medical lasers, wavefront modification, robotic movements, and intelligent vision software for automated, programmable ophthalmic surgery.

Keranova competes in the femtosecond laser-assisted cataract surgery (FLACS) and ophthalmic surgical robotics space against major players like Alcon (LenSx), Johnson & Johnson, and Bausch + Lomb. Its differentiation hinges on its proprietary Photoemulsification® process and its vision of a fully programmable, automated surgical suite.